BioGaia: Yet another meta-analysis confirms the effectiveness of BioGaia’s probiotic in infantile colic

In a newly presented systematic review the proof of effect on infantile colic was further strengthened for L. reuteri Protectis. The review is the eighth meta-analysis evaluating L. reuteri Protectis’ effect on infantile colic.

STOCKHOLM--()--Regulatory News:

Prior to the new review seven meta-analyses, evaluating different probiotics as well as non-probiotic treatments, have come to the same conclusion; that L. reuteri Protectis is effective in reducing crying time in colicky infants, especially in breastfed and mixed fed infants.

In the new, eighth review, with four studies on L. reuteri Protectis included, the proof was further strengthened. It combined raw data from these trials (Individual Participant Data Meta-Analysis, IPDMA), a method that yields more reliable estimates of treatment effect compared to traditional meta-analyses based on published data only. The analysis was undertaken according to the methods recommended by Cochrane (http://www.cochrane.org/about-us).

”A meta-analysis is considered the highest level of evidence of a health effect and now there are eight such meta-analyses with BioGaia ProTectis. While this clearly confirms BioGaia ProTectis as the number one treatment for infants with colic, it also reassures health care professionals around the world that they are suggesting an effective treatment when recommending BioGaia ProTectis drops to their patients”, says Axel Sjöblad, Managing Director, BioGaia.

The systematic review and meta-analysis (http://www.abstracts2view.com/pas/view.php?nu=PAS16L1_2710.4) was presented at the PAS (Pediatric Academic Societies) meeting in Baltimore, USA, 1 May 2016.

Latest press releases from BioGaia
2016-04-27 BioGaia guarantees rights issue in IBT
2016-04-27 IBT’s results for the first quarter of 2016
2016-04-25 BioGaia’s oral health probiotics to be launched in Hong Kong

BioGaia has published this information in accordance with the Swedish Securities Market Act. The information was issued for publication on 2 May 2016, 10:00 am CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com

This information was brought to you by Cision http://news.cision.com

Contacts

BioGaia
Axel Sjöblad, +46 8 555 293 00
Managing Director

Contacts

BioGaia
Axel Sjöblad, +46 8 555 293 00
Managing Director